Vaxxinity (VAXX) Competitors $0.0001 0.00 (0.00%) As of 07/23/2025 12:53 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsInsider TradesSEC FilingsTrendsBuy This Stock VAXX vs. SCPS, NAVB, EVLO, CMRA, GNCAQ, GNCA, ARDS, STAB, AMPE, and EFTRShould you be buying Vaxxinity stock or one of its competitors? The main competitors of Vaxxinity include Scopus BioPharma (SCPS), Navidea Biopharmaceuticals (NAVB), Evelo Biosciences (EVLO), Comera Life Sciences (CMRA), Genocea Biosciences (GNCAQ), Genocea Biosciences (GNCA), Aridis Pharmaceuticals (ARDS), Statera Biopharma (STAB), Ampio Pharmaceuticals (AMPE), and eFFECTOR Therapeutics (EFTR). These companies are all part of the "pharmaceutical products" industry. Vaxxinity vs. Its Competitors Scopus BioPharma Navidea Biopharmaceuticals Evelo Biosciences Comera Life Sciences Genocea Biosciences Genocea Biosciences Aridis Pharmaceuticals Statera Biopharma Ampio Pharmaceuticals eFFECTOR Therapeutics Scopus BioPharma (NASDAQ:SCPS) and Vaxxinity (NASDAQ:VAXX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, earnings, profitability, media sentiment and analyst recommendations. Does the media refer more to SCPS or VAXX? In the previous week, Scopus BioPharma's average media sentiment score of 0.00 equaled Vaxxinity'saverage media sentiment score. Company Overall Sentiment Scopus BioPharma Neutral Vaxxinity Neutral Do institutionals and insiders have more ownership in SCPS or VAXX? 82.9% of Vaxxinity shares are held by institutional investors. 5.1% of Scopus BioPharma shares are held by insiders. Comparatively, 64.1% of Vaxxinity shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Is SCPS or VAXX more profitable? Company Net Margins Return on Equity Return on Assets Scopus BioPharmaN/A N/A N/A Vaxxinity N/A N/A N/A Which has better valuation and earnings, SCPS or VAXX? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioScopus BioPharmaN/AN/A-$11.61MN/AN/AVaxxinityN/AN/A-$56.93M-$0.450.00 Which has more volatility & risk, SCPS or VAXX? Scopus BioPharma has a beta of -0.19, meaning that its share price is 119% less volatile than the S&P 500. Comparatively, Vaxxinity has a beta of -23.96, meaning that its share price is 2,496% less volatile than the S&P 500. SummaryScopus BioPharma and Vaxxinity tied by winning 2 of the 4 factors compared between the two stocks. Get Vaxxinity News Delivered to You Automatically Sign up to receive the latest news and ratings for VAXX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VAXX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VAXX vs. The Competition Export to ExcelMetricVaxxinityPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$13K$783.82M$5.57B$9.42BDividend YieldN/A4.84%4.05%3.99%P/E Ratio0.001.4028.1520.08Price / SalesN/A25.01401.6884.07Price / CashN/A19.5636.1958.45Price / Book0.006.928.625.83Net Income-$56.93M-$4.13M$3.24B$258.27M7 Day PerformanceN/A2.37%3.55%2.69%1 Month PerformanceN/A5.11%11.01%12.91%1 Year PerformanceN/A8.30%35.56%21.81% Vaxxinity Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VAXXVaxxinityN/A$0.00flatN/A-99.9%$13KN/A0.0090High Trading VolumeSCPSScopus BioPharmaN/A$0.00flatN/AN/A$13KN/A0.009NAVBNavidea BiopharmaceuticalsN/A$0.00flatN/A-50.0%$10K$8.13K0.0010EVLOEvelo BiosciencesN/A$0.00flatN/AN/A$9KN/A0.00120News CoverageOptions VolumeCMRAComera Life SciencesN/A$0.00flatN/AN/A$6K$1.00M0.002GNCAQGenocea BiosciencesN/AN/AN/AN/A$6KN/A0.0070GNCAGenocea BiosciencesN/AN/AN/AN/A$6K$1.91M0.0070ARDSAridis PharmaceuticalsN/A$0.00+∞N/AN/A$5KN/A0.0030Gap UpSTABStatera BiopharmaN/A$0.00flatN/A-83.3%$5KN/A0.0020Negative NewsHigh Trading VolumeAMPEAmpio PharmaceuticalsN/A$0.00-73.0%N/AN/A$3KN/A0.0020Gap DownEFTReFFECTOR Therapeutics0.0832 of 5 stars$0.00flatN/A-99.6%$1KN/A0.0010Upcoming Earnings Related Companies and Tools Related Companies Scopus BioPharma Competitors Navidea Biopharmaceuticals Competitors Evelo Biosciences Competitors Comera Life Sciences Competitors Genocea Biosciences Competitors Genocea Biosciences Competitors Aridis Pharmaceuticals Competitors Statera Biopharma Competitors Ampio Pharmaceuticals Competitors eFFECTOR Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VAXX) was last updated on 7/24/2025 by MarketBeat.com Staff From Our PartnersBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredBREAKING: The House just passed 3 pro-crypto bills!Experts Believe Altcoin Season is Here! With this new legislation in effect, crypto experts across the coun...Crypto 101 Media | SponsoredFREE GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...GoldCo Precious Metals | SponsoredThis New Rule Could Change EverythingA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big ...American Alternative | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaxxinity, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vaxxinity With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VAXX Stock Alerts